Stock Analiz

Evolent Health, Inc. EVH

Other Consumer Services · IPO 2015 · data as of November 13, 2026

$4.90Market cap $554M
Open the interactive analysis →

Evolent Health, Inc. (EVH) is a consumer discretionary company listed in the US with a market value of about $554M. In the twelve months to September 30, 2026 it had revenue of $2.3B and net income of -$508M, a net margin of -21.7%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (1/5).

Key numbers: a price to free cash flow of 15.1, 5-year revenue growth of 15% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 17% above the current price.

About Evolent Health

Evolent Health is listed in the US and classified in other consumer services, IPO year 2015. Revenue went from $254M in 2016 to $1.9B in 2025, growth of about 24.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 22% over three years (dilution for shareholders).

Score: 1.2 / 5

Value2/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year revenue growth above 10% a year
  • 5-year revenue growth above 8% a year
  • Positive free cash flow
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E11.0
P/FCF15.1
P/S0.2
P/B1.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield6.6%
Shareholder yield7.2%
Intrinsic value vs. price+17%

Growth and quality

Revenue growth (1 yr)-26.6%
Revenue growth (5 yrs, per year)15.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-8.4%
ROIC (5-yr avg.)-7.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2.3B$1.9B$2.6B$2.0B$1.4B$908M$925M$846M$627M$435M$254M
Net income-$508M-$535M-$62M-$113M-$19M-$38M-$334M-$302M-$53M-$61M-$160M
Free cash flow$37M——————-$78M-$60M-$56M-$51M
EPS (diluted)$-4.54$-5.07$-0.81$-1.28$-0.20$-0.44$-3.94$-3.67$-0.68$-0.94$-3.55
Net margin-21.7%-28.5%-2.4%-5.8%-1.4%-4.1%-36.1%-35.7%-8.4%-14.0%-62.8%
ROIC—-29.2%-2.3%-2.3%0.2%-3.4%-26.7%-22.2%-2.8%-5.9%-27.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 12 analysts is $6.00, 22% above the current price; targets range from $3.00 to $8.00; the consensus rating is “Buy”; expected EPS is $0.23 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Evolent Health stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 17% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Evolent Health pay a dividend?

Not currently.

Is Evolent Health a good stock to buy?

We do not give buy or sell advice. Evolent Health scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.